AN LC-MS/MS METHOD DEVELOPMENT AND VALIDATION FOR THE QUANTIFICATION OF ANTIVIRAL DRUGS IN PLASMA SAMPLES
DOI:
https://doi.org/10.22159/ijap.2026v18i2.56739Keywords:
Cabotegravir, Rilpivirine, HIV/AIDS, LC-MS/MS, Method validation, StabilityAbstract
Objective: A reliable and specific LC-MS/MS method was developed and validated for the simultaneous quantification of cabotegravir (CBTG) and rilpivirine (RLPV) in plasma samples.
Methods: Chromatographic separation was achieved on a Hypersil BDS C18 (50 × 4.6 mm, 5 µm) column maintained at 35 °C. The mobile phase consisted of 0.1% HCOOH, acetonitrile, and methanol in the ratio 10:80:10 (v/v/v). The injection volume was 10 µl**, and the autosampler temperature was maintained at 10 °C. The retention times for RLPV, internal standard, and CBTG were 2.00, 3.20, and 5.15 min, respectively.
Results: Accuracy ranged from 96.32% to 98.19% for CBTG and 95.57% to 97.00% for RLPV. The intra-and inter-day precision values were 0.39%–3.82% RSD for CBTG and 1.56%–4.55% RSD for RLPV mean recovery values at three QC levels were 96.14%–97.70% for CBTG and 96.06%–97.75% for RLPV. All stability assessments were within acceptance criteria.
Conclusion: The method is robust for the quantitative determination of CBTG and RLPV in biological samples and is suitable for application in forensic, quality-control, bioavailability, and bioequivalence studies.
References
1. Ferretti F, Boffito M. Rilpivirine long-acting for the prevention and treatment of HIV infection. Curr Opin HIV AIDS. 2018;13(4):300-7. doi: 10.1097/COH.0000000000000474, PMID 29794818.
2. Stellbrink HJ, Hoffmann C. Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxis. Curr Opin HIV AIDS. 2018;13(4):334-40. doi: 10.1097/COH.0000000000000480, PMID 29746267.
3. Cattaneo D, Gervasoni C. Pharmacokinetics and pharmacodynamics of cabotegravir a long-acting HIV integrase strand transfer inhibitor. Eur J Drug Metab Pharmacokinet. 2019;44(3):319-27. doi: 10.1007/s13318-018-0526-2, PMID 30387005.
4. Swindells S, Andrade Villanueva JF, Richmond GJ. Long-acting cabotegravir+rilpivirine as maintenance therapy: ATLAS week 48 results. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); 2019 Mar 4-7.
5. Orkin C, Arasteh K, Hernandez Mora MG. Long-acting cabotegravir+rilpivirine for HIV maintenance: FLAIR week 48 results. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); 2019 Mar.
6. Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen reports positive top-line phase 3 study results of investigational long-acting injectable HIV treatment regimen administered every two months; 2019. Available from: https://www.drugs.com/janssen-reports-positive-top-line-phase-3-study-results-investigational-long-acting-injectable-hiv-18243.html. [Last accessed on 03 Sep 2025].
7. Jackson AG, Else LJ, Mesquita PM, Egan D, Back DJ, Karolia Z. A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. Clin Pharmacol Ther. 2014;96(3):314-23. doi: 10.1038/clpt.2014.118, PMID 24862215.
8. Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M. Safety tolerability and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLOS Med. 2018;15(11):e1002690. doi: 10.1371/journal.pmed.1002690, PMID 30408115.
9. Margolis DA, Gonzalez Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised open-label phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499-510. doi: 10.1016/S0140-6736(17)31917-7, PMID 28750935.
10. Vejendla A, Talari S, Moturu R, Boddapati SN, Kola AE. Method development and validation for Cabotegravir and Rilpivirine by using HPLC and its degradants are characterized by LCMS and FTIR. Futur J Pharm Sci. 2021;7(1):226. doi: 10.1186/s43094-021-00355-8.
11. Ramoller IK, Abbate MT, Vora LK, Hutton AR, Peng K, Volpe Zanutto F. HPLC-MS method for simultaneous quantification of the antiretroviral agents rilpivirine and cabotegravir in rat plasma and tissues. J Pharm Biomed Anal. 2022;213:114698. doi: 10.1016/j.jpba.2022.114698, PMID 35259714.
12. Courlet P, Alves Saldanha S, Cavassini M, Marzolini C, Choong E, Csajka C. Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir cabotegravir doravirine and rilpivirine in people living with HIV. J Mass Spectrom. 2020;55(6):e4506. doi: 10.1002/jms.4506, PMID 32160389.
13. Bevers LA. Van Ewijk Beneken Kolmer EWJ, Te Brake HML, Burger DM. Development validation and clinical implementation of a UPLC-MS/MS bioanalytical method for simultaneous quantification of cabotegravir and rilpivirine E-isomer in human plasma. J Pharmacol Toxicol Methods. 2024;238:115832. doi: 10.1016/j.jpba.2023.115832.
14. Weld ED, Parsons TL, Gollings R, Mc Cauley M, Grinsztejn B, Landovitz RJ. Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of cabotegravir and rilpivirine from dried blood spots. J Pharm Biomed Anal. 2023;228:115307. doi: 10.1016/j.jpba.2023.115307, PMID 36842333.
15. European Medicines Agency. Guideline on Bioanalytical Method Validation. London: EMA; 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf. [Last accessed on 03 Sep 2025].
16. US Food and Drug Administration. Guidance for industry: bioanalytical method validation. In: Silver Spring, MD: FDA; 2018. Available https://www.fda.gov/downloads/drugs/guidances/ucm368107.pdf. [Last accessed on 03 Sep 2025].
17. Gallant JE, Thompson M, DeJesus E, Voskuhl GW, Wei X, Zhang H. Antiviral activity safety and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults. J Acquir Immune Defic Syndr. 2017;75(1):61-6. doi: 10.1097/QAI.0000000000001306, PMID 28196003.
18. Yee KL, Sanchez RI, Auger P, Liu R, Fan L, Triantafyllou I. Evaluation of doravirine pharmacokinetics when switching from efavirenz to doravirine in healthy subjects. Antimicrob Agents Chemother. 2017;61(2):e01757-16. doi: 10.1128/AAC.01757-16, PMID 27872069.
19. Dadhaniya T, Chaudhary K, Mehta P. Development of LC-MS/MS method for determination of iloperidone in rabbit plasma: application to a pharmacokinetic study. Int J Pharm Pharm Sci. 2013;7(4):294-7.
20. Deepan T, Basaveswara Rao MV, Dhanaraju MD. Bioanalytical method development and validation of canagliflozin in human plasma by LC-MS/MS. Asian J Pharm Clin Res. 2019;12(8):46-51. doi: 10.22159/ajpcr.2019.v12i18.33228.
21. Gurav P, Damle M. Bioanalytical method for estimation of teriflunomide in human plasma. Int J Pharm Pharm Sci. 2022;14(9):19-23. doi: 10.22159/ijpps.2022v14i9.45151.
22. Nimmakayala MR, Kolli D, Durga Bhavani PN. Bioanalytical method development and validation of maralixibat in rat plasma by LC-MS/MS detection and its application to a pharmacokinetic study. Int J App Pharm. 2023;15(4):166-72. doi: 10.22159/ijap.2023v15i4.47768.
23. Parmar I, Patel YA. Recent method development by analytical techniques of new FDA-approved drugs in 2021. Int J Curr Pharm Sci. 2022;14(3):17-21. doi: 10.22159/ijcpr.2022v14i3.1975.
24. Ravi Y, Bhikshapathi D, Cheruku S, Rajkamal B. Development of fast and simple LC-ESI-MS/MS technique for the quantification of regorafenib; application to pharmacokinetics in healthy rabbits. Curr Pharm Anal. 2021;17(4):554-63. doi: 10.2174/1573412916666191111144707.
25. Rozet E, Ceccato A, Hubert C, Ziemons E, Oprean R, Rudaz S. Analysis of recent pharmaceutical regulatory documents on analytical method validation. J Chromatogr A. 2007;1158(1-2):111-25. doi: 10.1016/j.chroma.2007.03.111, PMID 17420026.
26. Hubert P, Nguyen Huu JJ, Boulanger B, Chapuzet E, Chiap P, Cohen N. Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal part I. J Pharm Biomed Anal. 2004;36(3):579-86. doi: 10.1016/j.jpba.2004.07.027, PMID 15522533.
27. Lolla S, Gubbiyappa KS, Cheruku S, Bhikshapathi DV. Validation of an LC-MS/MS method for quantitation of fostemsavir in plasma. J Pharmacol Toxicol Methods. 2023;120:107254. doi: 10.1016/j.vascn.2023.107254, PMID 36863666.
28. Chapuzet E, Mercier N, Bervoas Martin S. Methodes chromatographiques de dosage dans les milieux biologiques: strategie de validation-rapport d’une commission SFSTP. STP Pharm Sci. 1997;7:169-94.
29. Krishnan VS, Bhikshapathi D, Cheruku S. Method development and validation for the quantification of abametapir in biological matrices by LC-ESI-MS/MS. Ind J Pharm Edu Res. 2024;58(3s):s1028-33. doi: 10.5530/ijper.58.3s.102.
Published
How to Cite
Issue
Section
Copyright (c) 2026 Raghavamma STV, DIVYA G
This work is licensed under a Creative Commons Attribution 4.0 International License.